Immunotech Biopharm (HKSE:06978) Cash-to-Debt : 0.36 (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Immunotech Biopharm Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Immunotech Biopharm's cash to debt ratio for the quarter that ended in Jun. 2024 was 0.36.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Immunotech Biopharm couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for Immunotech Biopharm's Cash-to-Debt or its related term are showing as below:

HKSE:06978' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15 Med: 3.18 Max: 16.56
Current: 0.15

During the past 7 years, Immunotech Biopharm's highest Cash to Debt Ratio was 16.56. The lowest was 0.15. And the median was 3.18.

HKSE:06978's Cash-to-Debt is ranked worse than
92.85% of 1482 companies
in the Biotechnology industry
Industry Median: 7.525 vs HKSE:06978: 0.15

Immunotech Biopharm Cash-to-Debt Historical Data

The historical data trend for Immunotech Biopharm's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Immunotech Biopharm Cash-to-Debt Chart

Immunotech Biopharm Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

16.56

3.18

0.53

0.39

0.15

Immunotech Biopharm Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial								0.53	0.58	0.39	0.36	0.15

Competitive Comparison of Immunotech Biopharm's Cash-to-Debt

For the Biotechnology subindustry, Immunotech Biopharm's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunotech Biopharm's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunotech Biopharm's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Immunotech Biopharm's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Immunotech Biopharm Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Immunotech Biopharm's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	193.569	/	(26.993	+	473.053)
	=	0.39

Immunotech Biopharm's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	156.433	/	(335.967	+	104.662)
	=	0.36

Immunotech Biopharm (HKSE:06978) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Immunotech Biopharm Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Immunotech Biopharm's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunotech Biopharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunotech Biopharm Ltd (HKSE:06978) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176

Website

https://www.eaal.net

Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.

Executives

Jung Hyun Chul
Evodevo Ltd
Yan Kaijing	2501 Other
Xi Zang Jia Ze Chuang Ye Tou Zi You Xian Gong Si	2101 Beneficial owner
Jiang Su Ji Chuan Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Cao Longxiang	2201 Interest of corporation controlled by you
Cao Fei	2201 Interest of corporation controlled by you
Tian Jin Fu Hua De Ke Ji Kai Fa You Xian Gong Si	2501 Other
Yan Xijun	2501 Other
Wu Naifeng	2501 Other
Tasly (hong Kong) Pharmaceutical Investment Limited	2501 Other
Li Yunhui	2501 Other
Hua Run San Jiu Yi Yao Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
China Resources Pharmaceutical Group Limited	2201 Interest of corporation controlled by you
China Resources Company Limited	2201 Interest of corporation controlled by you

Immunotech Biopharm Headlines

No Headlines